Over 40 years of valuable contribution to healthcare

Report
Abbott Diagnostics - over
of valuable contributions
to health care.
1
SB HD NICD 29 V2
Blood donations are safer than ever…
Source: Nat. Med. 2000; 6:1082-1086
HP_12_5607
SB HD NICD v2.0
29 V2
2
YESTERDAY, TODAY, AND TOMORROW
Agar gel diffusion technique (AGD) / Ouchterlony method
• Simple test to perform, but
• Subjective and difficult visual reading interpretation
• Very insensitive.
In 1972 Abbott developed one of the first hepatitis surface antigen test,
AUSRIA-125, beginning our history as the world leader in
hepatitis diagnostics.
3
HP_12_5607
SB HD NICD v2.0
29 V2
YESTERDAY, TODAY, AND TOMORROW
Accurate Diagnosis of a Changing Target has Significant Patient Impact
Hemodialysis Patient
•
•
•
•
•
Patient with kidney transplant for 10 years
Due to transplant failure on dialysis on 2003
Initial test negative, Abbott HBsAg positive
Confirmed by further serology and DNA test
HBV with changes in 6 amino acid positions: T115R,
P120Q, S154L, E164V, Q181R, S210R
• Avoided potential HBV transmission
Sussitz S et al., Poster at 5th Int. Symposium on Molecular Diagnostics
in Laboratory Medicine, Graz, June 10-12, 2004
4
HP_12_5607
SB HD NICD v2.0
29 V2
YESTERDAY, TODAY, AND TOMORROW
Abbott Diagnostics continues to enhance detection accuracy
The ARCHITECT HBsAg Qualitative II assay
Detects the most common HBV mutants
Improved Mutant detection compared to ARCHITECT
HBsAg Qualitative
ARCHITECT HBsAg Qualitative II 34-6817/R02 package insert
5
HP_12_5607
SB HD NICD v2.0
29 V2
YESTERDAY, TODAY, AND TOMORROW
HCV Core Antigen enables early routine detection
A window period of 30-70 days after exposure
exists where specific antibodies to HCV antigens
are not detected (1)
(1) Leary et al,J. Med Virol., 78:1436-1440 (2006) Schematic representation adapted
from S. Muerhoff Viral Hepatitis, 2004, Miedouge et al, J. Clinical Virol., 48 (2010) 1821 & George Dawson Journal Medical Virology 79:S54-S58(2007)
1.Medici et al,J. Clin Virol. 2011.
2.Miedouge et al J. Clin Viral., 2010;48:18-21.
3.Mederacke et al,J. Clin Viral., 2009;46:210-215.
4.Moscato et al, lntervirology 2011;54:61-65.
5.Gerlich and Vockel,GHI Dec 2009.
HP_12_5607
SB HD NICD v2.0
29 V2
YESTERDAY, TODAY, AND TOMORROW
HP_12_5607
SB HD NICD v2.0
29 V2
YESTERDAY, TODAY, AND TOMORROW
Our continued innovation to support
you in achieving cost-effective,
timely, and reliable clinical
laboratory results to impact both
• individual patient management
• the overall health care system
8
HP_12_5607
SB HD NICD v2.0
29 V2
9

similar documents